Stay updated on Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial

Sign up to get notified when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a clinical trial involving the assessment of nanoliposomal irinotecan-containing regimens in patients with metastatic pancreatic adenocarcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:30:25.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to include detailed eligibility criteria for participants, specifying requirements such as confirmed adenocarcinoma of the pancreas and other health conditions. Previously, this section had no information provided.
    Difference
    20%
    Check dated 2024-05-22T20:59:12.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:21:17.000Z thumbnail image

Stay in the know with updates to Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.